Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.
Publication
, Conference
Dejan, J; Rugo, HS; Chia, SKL; Lerebours, F; Ruiz-Borrego, M; Drullinsky, P; Ciruelos, EM; Neven, P; Park, YH; Arce, CH; Gu, E; Joshi, M ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Dejan, J., Rugo, H. S., Chia, S. K. L., Lerebours, F., Ruiz-Borrego, M., Drullinsky, P., … Turner, N. C. (2022). Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Dejan, Juric, Hope S. Rugo, Stephen K. L. Chia, Florence Lerebours, Manuel Ruiz-Borrego, Pamela Drullinsky, Eva M. Ciruelos, et al. “Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Dejan J, Rugo HS, Chia SKL, Lerebours F, Ruiz-Borrego M, Drullinsky P, et al. Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Dejan, Juric, et al. “Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Dejan J, Rugo HS, Chia SKL, Lerebours F, Ruiz-Borrego M, Drullinsky P, Ciruelos EM, Neven P, Park YH, Arce CH, Gu E, Joshi M, Roux E, Akdere M, Turner NC. Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with hormone receptorpositive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study. JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences